BCDA has an upcoming CardiAMP Heart Failure DSMB review on the 30th of this month (August). Although the treatment indicated no significant safety concerns, I have reasonable doubt that this won't go through to be accepted by the FDA; the Phase III to NDA/BLA is about a 58.1% chance, the NDA/BLA to Approval is a 85.3% chance, and then the Phase I to Approval is a...